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Diabetes mellitus (DM) (Type 1 (T1DM) and Type 2 (T2DM)) and hypertension (HTN) are 
associated with subtle cognitive dysfunction; however, few studies have explored the cognitive 
and electroencephalography (EEG) changes that occur in these conditions. The present cross-
sectional study assessed cognitive performance (global and domain-specific) in clinical 
(T1DM, T2DM, and HTN) and non-clinical samples using established cognitive assessments 
and EEG, and investigated their associations with blood pressure (systolic (SBP) and diastolic 
(DBP)) and blood glucose level (BGL). 
 
Results were obtained from 94 study participants divided into four groups: non-clinical (n = 
49), T1DM (n = 13), T2DM (n = 17), and HTN (n = 15). The experimental protocol was 
commenced by obtaining pre-study BP measurements and a BGL measurement. Participant 
lifestyle factors and disease-specific variables (e.g. HbA1c, age of disease onset, etc.) were 
obtained using the Lifestyle Appraisal Questionnaire (LAQ) and disease-specific 
questionnaires, respectively. Brain activity was then measured using a 32-channel EEG over 
two five-minute study phases (baseline (quiet sitting) and active (Stroop Test)). Subsequently, 
two reliable and validated cognitive screening tools were administered, the Mini-Mental State 
Examination (MMSE) and the Cognistat. The study was concluded with post-study BP 
measurements and a BGL measurement. 
 
No significant difference was found in global or domain-specific cognitive performance 
between the groups. In the non-clinical group, post-study BGL was inversely associated with 
total MMSE score (p < 0.05; r = - 0.32). In the T1DM and T2DM groups, higher BGL was 
significantly associated (p < 0.05) with theta activity in anterior brain regions, while 
glycosylated haemoglobin (HbA1C) and disease duration were found to be significantly 
associated (p < 0.05) with slow-wave oscillations. In the HTN group, higher SBP and DBP was 





These findings provide novel insight into the associations between blood pressure (SBP and 
DBP) and BGL and EEG activity in non-clinical and clinical groups. The data obtained suggest 
that the EEG can consistently detect changes in oscillatory brain activity linked to small changes 
in BP and BGL, identifying the EEG as a potential neurophysiological instrument for early 
screening for the subtle changes in cognition linked to both DM and HTN. Future use of EEG 
as a screening tool could avert adverse cognitive outcomes linked to these chronic diseases, 
such as Alzheimer’s disease (AD) and dementia, and help reduce the substantial socioeconomic 
and emotional burden associated with them. 
 
